Comparison of frequency of silent cerebral infarction as assessed by serum neuron specific enolase in patients with non-valvular atrial fibrillation: Warfarin versus direct oral anticoagulant

References

• Minami Y, Haruki S, Jujo K, et al. Elevated D-dimer levels predict an adverse outcome in hospitalized patients with acute decompensated heart failure. Int J Cardiol. 2016;204:2–44.
   Web of Science ®Google Scholar
• Siachos T, Vanbakel A, Feldman DS, et al. Silent strokes in patients with heart failure. J Card Fail. 2005;11:85–489.
   Web of Science ®Google Scholar
• Price TR, Manolio TA, Kronmal RA, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in communitydwelling older adults. The cardiovascular health study. CHS collaborative research group. Stroke. 1997;28(6):1158–1164.
   PubMed Web of Science ®Google Scholar
• Avdibegovic E, Becirovic E, Salimbasic Z, et al. Cerebral cortical atrophy and silent brain infarcts in psychiatric patients. Psychiatr Danub. 2007;19:49–55.
   PubMed Web of Science ®Google Scholar
• Wright CB, Festa JR, Paik MC, et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke. 2008;39(3):800–805.
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215–1222.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Fujikawa T, Yanai I, et al. Cognitive dysfunction in recovered depressive patients with silent cerebral infarction. Neuropsychobiology. 2002;45(1):12–18.
   PubMed Web of Science ®Google Scholar
• Bokura H, Kobayashi S, Yamaguchi S, et al. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis. 2006;15(2):57–63.
   PubMedGoogle Scholar
• Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28(10):1932–1939.
   PubMed Web of Science ®Google Scholar
• Liebetrau M, Steen B, Hamann GF, et al. Silent and symptomatic infarcts on cranial computerized tomography in relation to dementia and mortality: a population-based study in 85-year-old subjects. Stroke. 2004;35(8):1816–1820.
   PubMed Web of Science ®Google Scholar
• Stevens H, Jakobs C, de Jager AE, et al. Neuronespecific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke. Eur J Clin Invest. 1999;29:6–11.
   PubMed Web of Science ®Google Scholar
• Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis. 2005;20(4):213–219.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Goksuluk H, Gulec S, Ozcan OU, et al. Usefulness of Neuron-Specific enolase to detect silent neuronal ischemia after percutaneous coronary intervention. Am J Cardiol. 2016;117(12):1917–1920.
   PubMed Web of Science ®Google Scholar
• Goksuluk H, Gulec S, Ozyuncu N, et al. Comparison of frequency of silent cerebral infarction after coronary angiography and stenting with transradial versus transfemoral approaches. Am J Cardiol. 2018;122(4):548–553.
   PubMed Web of Science ®Google Scholar
• Ozyuncu N, Gulec S, Kaya CT, et al. Relation of acute decompensated heart failure to silent cerebral infarcts in patients with reduced left ventricular ejection fraction. Am J Cardiol. 2019;123(11):1835–1839.
   PubMed Web of Science ®Google Scholar
• Ozyuncu N, Gulec S, Goksuluk H, et al. Relationship between silent cerebral infarcts and quality of anticoagulations in patients with prosthetic mitral valves. Anatol J Cardiol. 2021;25(3):191–195.
   PubMed Web of Science ®Google Scholar
• Quevedo AG, García SG, Díaz ZH, et al. Serum neuron specific enolase could predict subclinical brain damage and the subsequent occurrence of brain related vascular events during follow up in essential hypertension. J Neurol Sci. 2016;363:158–163.
   PubMed Web of Science ®Google Scholar
• Chan PH, Li WH, Hai JJ, et al. Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation. Can J Cardiol. 2016;32:1247–1248. e23.
   Web of Science ®Google Scholar
• Blum D, Beaubien-Souligny W, Battistella M, et al. Quality improvement program improves time in therapeutic range for hemodialysis recipients taking warfarin. Kidney Int Rep. 2020;5(2):159–164.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. Circulation. 1995;92(8):2178–2182.
   PubMed Web of Science ®Google Scholar
• Group ES. Silent brain infarction in nonrheumatic atrial fibrillation: European atrial fibrillation trial. Neurology. 1996;46:159–165.
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Iguchi M, Shimizu S, et al. Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis. 2012;21(4):310–317.
   PubMed Web of Science ®Google Scholar
• Kalantarian S, Ay H, Gollub RL, et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Ann Intern Med. 2014;161(9):650–658.
   PubMed Web of Science ®Google Scholar
• Hahne K, Mönnig G, Samol A. Atrial fibrillation and silent stroke: links, risks, and challenges. Vasc Health Risk Manag. 2016;12(3):65–74.
   PubMedGoogle Scholar
• Strach K, Meyer C, Hackenbroch M, et al. Long-term fate of left atrial thrombi and incidence of cerebral embolism under continuous anticoagulation therapy. Rofo. 2005;177(12):1706–1712.
   PubMedGoogle Scholar
• Sato H, Koretsune Y, Fukunami M, et al. Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation. Circ J. 2004;68(5):410–416.
   PubMed Web of Science ®Google Scholar
• Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol. 1998;55(11):1475–1482.
   PubMed Web of Science ®Google Scholar
• Sugioka K, Takagi M, Sakamoto S, et al. Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study. Am Heart J. 2015;169(6):783–790.
   PubMed Web of Science ®Google Scholar
• Rastegar R, Harnick DJ, Weidemann P, et al. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol. 2003;41(4):603–610.
   PubMed Web of Science ®Google Scholar
• Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. ATVB. 1997;17(11):3191–3195.
   Web of Science ®Google Scholar
• Hart RG, Pearce LA, Miller VT, et al. Cardioembolic versus non-cardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10(1):39–43.
   PubMed Web of Science ®Google Scholar
• Oh SH, Lee JG, Na SJ, et al. Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron specific enolase level. Arch Neurol. 2003;60(1):37–41.
   PubMedGoogle Scholar
• Haque A, Polcyn R, Matzelle D, et al. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. Brain Sci. 2018;8(2):33.
   PubMed Web of Science ®Google Scholar